How do you study palliative care? Come discuss the science behind the recent Hepatology Communications article on the “Surprise Question,” a clinician-based prognostication tool initially developed to identify patients who may benefit from palliative care interventions with Dr. Nneka Ufere. Read the article here: https://journals.lww.com/hepcomm/fulltext/2025/08010/accuracy_of_the__surprise_question__in_predicting.7.aspx
 
12:45-12:55 PM- Presentation
12:55-1:15 PM- Audience Q&A and Discussion
 

Late-Breaking Abstract Parallel sessions feature oral presentations from the authors of cutting-edge, highly-rated abstracts submitted for presentation at The Liver Meeting.

In this session, investigators will present cutting-edge clinical studies on transplant and discoveries from consortia and registries.

Have questions about ScholarOne or technical questions about submitting to Hepatology, Liver Transplantation, or Hepatology Communications? Come ask our Editorial Office staff!
Friday, Nov 7 and Monday, Nov 10 at 9:45 AM- 10:15 AM
AASLD Publications Staff: hepatology@aasld.org, livertransplantation@aasld.org, hepcomm@aasld.org
 

Late-Breaking Abstract Parallel sessions feature oral presentations from the authors of cutting-edge, highly-rated abstracts submitted for presentation at The Liver Meeting.

In this session, presenters will explore emerging research on alcohol-associated liver disease (ALD), with a focus on severe alcohol-associated hepatitis (SAH). The session will highlight long-term outcomes following hospitalization and early liver transplantation for SAH, as well as introduce a novel therapeutic approach to its treatment. Additionally, it will examine a newly identified genetic risk modifier for ALD and investigate the potential influence of cannabis use on disease risk. Together, these abstracts aim to deepen understanding of disease mechanisms, treatment strategies, and risk factors in ALD.

Please join us for an engaging and highly anticipated educational panel presentation focusing on a treatment option for patients with MASH, including the clinical data and patient cases.

Industry Supporter: Madrigal